Skip to Main Content

Paper Details

Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.
Eur J Cancer
29
2023
Advanced Prostate Cancer, COVID-19, Prostate Cancer, advanced prostate cancer, castration-resistant prostate cancer, healthcare, hormone-sensitive prostate cancer, locally advanced prostate cancer, mCRPC, mHSPC, metastatic, metastatic and, metastatic and/or castration-resistant prostate cancer, metastatic castration-resistant prostate cancer, metastatic, hormone-sensitive prostate cancer, nmCRPC, non-metastatic, castration-resistant prostate cancer, oligometastatic and oligoprogressive prostate cancer, oligometastatic prostate cancer, patient, patients, pre, prostate cancer
Author NameAffiliation
Johann S de BonoThe Institute of Cancer Research, UK Royal Marsden Hospital
Nicolas MottetUniversity Jean Monnet
Eric J SmallUCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco
Emmanuel S AntonarakisUniversity of Minnesota Masonic Cancer Center
Gerhardt AttardUniversity College London Cancer Institute
Tomasz M BeerKnight Cancer Institute, Oregon Health & Science University
Himisha BeltranDana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School
Himisha BeltranDana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School
Anders BjartellSkane University Hospital
Alberto BrigantiIRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University
Robert G BristowUniversity of Manchester, UK Christie NHS Trust and CRUK Manchester Institute and Cancer Centre
Heather H ChengUniversity of Washington, Fred Hutchinson Cancer Center
Kim N ChiUniversity of British Columbia
Eleni EfstathiouHouston Methodist Cancer Center
Christopher P EvansUniversity of California Davis School of Medicine
Felix Y FengUniversity of California san francisco
Mark FrydenbergMonash University
Martin E GleaveUniversity of British Columbia
Celestia S HiganoUniversity of British Columbia
Maha HussainRobert H. Lurie Comprehensive Cancer Center, Northwestern University
Brandon A MahalUniversity of Miami Sylvester Cancer Center
Joaquin MateoDepartment of Medical Oncology and Prostate Cancer Translational Research Group. Vall d'Hebron Institute of Oncology (VHIO) and Vall d'Hebron University Hospital
Niven MehraRadboud University Medical Center
Michael J MorrisMemorial Sloan Kettering Cancer Center
Declan G MurphyPeter MacCallum Cancer Centre, University of Melbourne
Paul L NguyenBrigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School
William K OhIcahn School of Medicine at Mount Sinai, The Tisch Cancer Institute
Piet OstGhent University
Colin C PritchardUniversity of Washington
Dana E RathkopfMemorial Sloan Kettering Cancer Center
Robert E ReiterUniversity of California Los Angeles
Mark A RubinBern Center for Precision Medicine and Department for Biomedical Research
Mark A RubinBern Center for Precision Medicine and Department for Biomedical Research
Fred SaadCentre Hospitalier de Universite de Montreal
Oliver SartorTulane Cancer Center
Howard I ScherMemorial Sloan Kettering Cancer Center, Weill Cornell Medical College
Daniel E SprattUniversity Hospitals Seidman Cancer Center
Cora N SternbergEnglander Institute for Precision Medicine, Meyer Cancer Center, New York Presbyterian Hospital
Mary-Ellen TaplinDana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School
Derya TilkiMartini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Koc University Hospital
Inge M van OortRadboud University Medical Center
Neha VapiwalaAbramson Cancer Center, University of Pennsylvania
Evan Y YuUniversity of Washington and Fred Hutchinson Cancer Center
Almudena ZapateroHospital Universitario de La Princesa, Health Research Institute
  • 1 - 44

Datasets